Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity: 2022-2025
Historic Liabilities and Shareholders Equity for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $412.9 million.
- Entrada Therapeutics' Liabilities and Shareholders Equity fell 25.55% to $412.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 11.44%. This contributed to the annual value of $526.3 million for FY2024, which is 12.18% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Liabilities and Shareholders Equity is $412.9 million, which was down 8.00% from $448.8 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Liabilities and Shareholders Equity ranged from a high of $582.0 million in Q2 2024 and a low of $252.1 million during Q4 2022.
- Its 3-year average for Liabilities and Shareholders Equity is $495.1 million, with a median of $486.5 million in 2025.
- Per our database at Business Quant, Entrada Therapeutics' Liabilities and Shareholders Equity skyrocketed by 86.15% in 2023 and then fell by 25.55% in 2025.
- Quarterly analysis of 4 years shows Entrada Therapeutics' Liabilities and Shareholders Equity stood at $252.1 million in 2022, then spiked by 86.15% to $469.2 million in 2023, then grew by 12.18% to $526.3 million in 2024, then fell by 25.55% to $412.9 million in 2025.
- Its Liabilities and Shareholders Equity stands at $412.9 million for Q3 2025, versus $448.8 million for Q2 2025 and $486.5 million for Q1 2025.